Evidence map›Paper›PMID 40921925›Full record

ArticleJournal of molecular histology2025

Tongxinluo alleviates myocardial ischemia-reperfusion injury by inhibiting the pyroptosis of endothelial cells via the NLRP3/Caspase-1/GSDMD signaling pathway.

Xuan Wu, Yun-Long Hou, Tong-Xing Wang, Li-Ping Chang, Hong-Ru Zhou, Ming-Ye Wang, Yi-Ling Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xuan WuDepartment of Cardiology, The Third Hospital of Hebei Medical University, Shijiazhuang, 050051, China.
Yun-Long HouNational Key Laboratory for Innovation and Transformation of Luobing Theory, Shijiazhuang, 050035, China.
Tong-Xing WangNational Key Laboratory for Innovation and Transformation of Luobing Theory, Shijiazhuang, 050035, China.
Li-Ping ChangNational Key Laboratory for Innovation and Transformation of Luobing Theory, Shijiazhuang, 050035, China.
Hong-Ru ZhouThe First Affiliated Hospital of Henan University of CM, Zhengzhou, 450000, China.
Ming-Ye WangCollege of Integrated Traditional Chinese and Western Medicine, Hebei University of Chinese Medicine, Shijiazhuang, 050091, China.
Yi-Ling WuHebei Medical University, No. 361, Zhongshan East Road, Shijiazhuang, 050017, China. wuyiling10g@126.com.

Funding

The Scientific Research Project of the Hebei Provincial Administration of Traditional Chinese Medicine funded this study 2022216
6 · The paper itself

Abstract

Numerous people experiencing acute myocardial infarction are also experiencing myocardial ischemia-reperfusion injury (MIRI). Pyroptosis is a core mechanism in MIRI. Tongxinluo (TXL) has a significant protective effect on endothelial cell function. This study utilized network pharmacology to investigate how TXL improves ischemia/reperfusion injury through targeting dysfunction of endothelial cells. Network pharmacology analysis identified 40 key targets through which TXL improves I/R by regulating endothelial dysfunction. We administered TXL (1.5 g/kg/d, oral gavage) to C57BL/6 mice for 7 days before inducing I/R injury, and used 400 μg/ml TXL for in vitro H/R injury in HUVECs. We extensively investigated the effects of TXL on pyroptosis in heart tissue and explored the underlying mechanism through biochemical assays, histopathology, and Western blot analysis. Network pharmacology analysis revealed that TXL targets primarily act on pyroptosis and inflammatory pathways. TXL pretreatment significantly improved cardiac function with increased EF% and decreased LVESV and LVEDV compared to the model group. Myocardial enzymes (CK, CKMB, LDH, cTnI) were markedly reduced by TXL pretreatment. TXL significantly decreased IL-18 and IL-1β levels in serum and reduced neutrophil infiltration in the ischemic area. TXL administration notably downregulated the expression of pyroptosis-related factors (NF-κB, NLRP3, cleaved-Caspase1, GSDMD) in both MIRI mouse model and H/R-treated HUVECs. Molecular docking showed that ginsenoside Rg3, a key TXL component, can directly interact with NLRP3 and GSDMD. TXL has a significant protective effect on endothelial cell function during I/R injury through inhibition of pyroptosis via the NLRP3/Caspase-1/GSDMD signaling pathway, preserving microcirculation barrier integrity.

Indexed as

Caspase 1Drugs, Chinese HerbalEndothelial CellsIntracellular Signaling Peptides and ProteinsMyocardial Reperfusion InjuryNLR Family, Pyrin Domain-Containing 3 ProteinPhosphate-Binding ProteinsPyroptosisSignal TransductionAnimalsDisease Models, AnimalGasderminsHumansHuman Umbilical Vein Endothelial CellsMaleMiceCaspase 1Drugs, Chinese HerbalGasderminsGsdmd protein, mouseIntracellular Signaling Peptides and ProteinsNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mousePhosphate-Binding ProteinstongxinluoCardiac microcirculationEndothelial cellMyocardial ischemia–reperfusion injuryNetwork pharmacologyPyroptosisTongxinluo

Identifiers

PMID40921925
PMCPMC12417232

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.